Transfusion-Related Risks of Intradermal Allogeneic Lymphocyte Immunotherapy: Single Cases in a Large Cohort and Review of the Literature
Article first published online: 2 AUG 2006
American Journal of Reproductive Immunology
Volume 56, Issue 3, pages 157–171, September 2006
How to Cite
Kling, C., Steinmann, J., Flesch, B., Westphal, E. and Kabelitz, D. (2006), Transfusion-Related Risks of Intradermal Allogeneic Lymphocyte Immunotherapy: Single Cases in a Large Cohort and Review of the Literature. American Journal of Reproductive Immunology, 56: 157–171. doi: 10.1111/j.1600-0897.2006.00413.x
- Issue published online: 2 AUG 2006
- Article first published online: 2 AUG 2006
- Submitted January 20, 2006; accepted May 15, 2006.
- human immunodeficiency virus;
- in vitro fertilization;
- neonatal alloimmune thrombocytopenia;
- rhesus hemolytic disease
Problem Lymphocyte immunotherapy (LIT) is applied in infertility treatment. Moreover, it has been suggested for prevention of rhesus D-hemolytic disease and as a vaccine for reduction of human immunodeficiency virus-1 susceptibility. Although transfusion-related problems have been rarely reported they were a matter of debate. Here we discuss extensive single-center experience with intradermal LIT for implantation failure and recurrent miscarriages.
Method of study Retrospective 2- to 3-year follow-up of in vitro fertilization couples treated during 1996–2002 (feedback 2848/3041 = 93%), registering 930 deliveries. Prospective survey for acute reactions for 2000–2003 (feedback 2687/3246 = 83%). Review of the literature.
Results Infections of the patient and transplant rejection later in life are minor residual risks. Post-transfusion purpura was suspected once but not verified. Anaphylaxis or malignancy were not promoted. Fetal/newborn alloimmune disease (severe hemolytic disease, thrombocytopenia, neutropenia) were not observed.
Conclusion Based on microbiological, immunological, and hematological testing the risks of intradermal LIT are low.